<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02691949</url>
  </required_header>
  <id_info>
    <org_study_id>S10418-4</org_study_id>
    <nct_id>NCT02691949</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Mycophenolate Mofetil in subjectswithSjogren's Syndrome</brief_title>
  <official_title>Efficacy and Safety of Mycophenolate Mofetil in subjectswithSjogren's Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaohsiung Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Past literature showed encouraging effects of mycophenolate on dryness symptoms and quality&#xD;
      of life in patients with Sjogren's syndrome. Mycophenolate also has excellent&#xD;
      immunomodulation effects in lupus nephritis. Currently Mycophenolate is only used in lupus&#xD;
      nephritis and organ transplant. It is unknown whether low dosage of mycophenolate mofetil&#xD;
      could be used to improve ocular dryness and oral dryness in patients with Sjogren's syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sjogren's syndrome is one of the most common autoimmune diseases in Taiwan. It is&#xD;
      characterized by keratoconjunctivitis sicca and xerostomia. Although it is well established&#xD;
      that Sjogren's syndrome is caused by infiltration and destruction of lacrimal gland and&#xD;
      salivary gland by lymphocytic cells, effective treatment of patients' symptoms is lacking.&#xD;
      Hydroxychloroquine is the most well-studied medication in Sjogren's syndrome. However, recent&#xD;
      clinical trials showed disappointing effects of hydroxychloroquine in Sjogren's syndrome.&#xD;
      Thus there is an unmet need to find effective treatment for patient's bothering symptoms.&#xD;
&#xD;
      Mycophenolate is a selective inhibitor of inosinemonophosphate dehydrogenase which leads to&#xD;
      inhibition of the de novo pathway of nucleotide synthesis. The antiproliferative effect of&#xD;
      mycophenolate mainly affects activated T and B lymphocytes because the proliferation of these&#xD;
      cells is critically dependent on the de novo purine synthesis compared with other eukaryotic&#xD;
      cells. Since these lymphocytes have been suggested to play a pivotal role in the inflammation&#xD;
      and immunopathogenesis of Sjogren's syndrome, mycophenolate might be a promising agent in the&#xD;
      treatment of Sjogren's syndrome.&#xD;
&#xD;
      Past literature showed encouraging effects of mycophenolate on dryness symptoms and quality&#xD;
      of life in patients with Sjogren's syndrome. Mycophenolate also has excellent&#xD;
      immunomodulation effects in lupus nephritis. Currently mycophenolate is only used in lupus&#xD;
      nephritis and organ transplant. It is unknown whether low dosage of mycophenolate could be&#xD;
      used to improve ocular dryness and oral dryness in patients with Sjogren's syndrome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Composite Index of Sjogren's syndrome</measure>
    <time_frame>baseline, 28 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ocular dryness</measure>
    <time_frame>baseline, 28 week</time_frame>
    <description>We will calculate the change of ocular dryness from baseline to week 28 (0mm [very bad] to 100mm [very good])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>physician visual analog scale (VAS)</measure>
    <time_frame>baseline, 28 week</time_frame>
    <description>We will calculate the change of physician VAS from baseline to week 28 (0mm [very bad] to 100mm [very good])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Schirmer's test</measure>
    <time_frame>baseline, 28 week</time_frame>
    <description>We will calculate the change of Schirmer's test results from baseline to week 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saxon's test</measure>
    <time_frame>baseline, 28 week</time_frame>
    <description>We will calculate the change of Saxon's test results from baseline to week 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart rate</measure>
    <time_frame>baseline, 28 week</time_frame>
    <description>resting heart rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>baseline, 28 week</time_frame>
    <description>resting blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>leukocyte count</measure>
    <time_frame>baseline, 28 week</time_frame>
    <description>WBC count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hb level</measure>
    <time_frame>baseline, 28 week</time_frame>
    <description>Hb level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>platelet count</measure>
    <time_frame>baseline, 28 week</time_frame>
    <description>platelet count</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Sjogren's Syndrome</condition>
  <arm_group>
    <arm_group_label>Mycophenolate mofetil standard</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mycophenolate mofetil 250mg 2# twice per day (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mycophenolate sodium low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mycophenolate mofetil 250mg 1# twice per day (BID)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>mycophenolate mofetil 1# BID-2# BID</description>
    <arm_group_label>Mycophenolate mofetil standard</arm_group_label>
    <arm_group_label>Mycophenolate sodium low</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of primary Sjogren's syndrome based on the 2002 American-European Consensus&#xD;
             criteria&#xD;
&#xD;
          2. Aged 20 to 75 years&#xD;
&#xD;
          3. Stable doses of oral corticosteroids(≦5mg/d) for at least 4 weeks before enrollment&#xD;
&#xD;
          4. Intolerance or inadequate response to hydroxychloroquine and (pilocarpine or&#xD;
             cevimeline), defined as less than 50mm on at least 2 of VAS including:&#xD;
&#xD;
               1. global assessment : 0mm (very bad) to 100mm (very good)&#xD;
&#xD;
               2. pain: 0mm (very bad) to 100mm (very good)&#xD;
&#xD;
               3. fatigue: 0mm (very bad) to 100mm (very good)&#xD;
&#xD;
               4. xerostomia: 0mm (very bad) to 100mm (very good)&#xD;
&#xD;
          5. Adequate contraception for patients of childbearing potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Receiving biologics during the 6 previous months or any other immunosuppressant&#xD;
             (methotrexate, cyclophosphamide, cyclosporine, azathioprine, mycophenolate mofetil&#xD;
             (MMF), mycophenolate sodium, leflunomide, penicillamine) during the previous month&#xD;
&#xD;
          2. Any one of laboratory abnormalities:&#xD;
&#xD;
               1. Serum creatinine ≥2 mg/dl&#xD;
&#xD;
               2. aspartate aminotransferase (AST) or alanine transaminase (ALT) more than 1.5 x&#xD;
                  upper normal range of the laboratory&#xD;
&#xD;
               3. Leukopenia (WBC&lt;4000/μl)&#xD;
&#xD;
               4. Hb ≤ 9 g/dl (5.6 mmol/l) for males and 8.5 g/dl (5.3 mmol/l) for females&#xD;
&#xD;
               5. Neutrophil less than 1.5 x 109/l&#xD;
&#xD;
               6. Platelet count less than 150 x 109/l&#xD;
&#xD;
          3. History of other autoimmune diseases&#xD;
&#xD;
          4. Use topical cyclosporine eyedrops, antihistamine, anticholinergic, antidepressant, or&#xD;
             antipsychotic drug with possible effects on ocular dryness or oral dryness within 1&#xD;
             month&#xD;
&#xD;
          5. Pregnant or lactating women&#xD;
&#xD;
          6. Previous or current malignancies adequately controlled less than 5 years, hepatitis B,&#xD;
             hepatitis C, HIV infection, tuberculosis, or diabetes&#xD;
&#xD;
          7. Subjects with serious infections requiring hospitalization within the last 12 months&#xD;
&#xD;
          8. Subjects with herpes zoster or cytomegalovirus that resolved less than 2 months before&#xD;
             enrollment&#xD;
&#xD;
          9. Subjects who have received any live vaccines within 3 months&#xD;
&#xD;
         10. Underlying cardiac, pulmonary, metabolic, renal, hepatic, gastrointestinal,&#xD;
             haematological or neurological conditions, chronic or latent infectious diseases or&#xD;
             immune deficiency which places the patient at an unacceptable risk for participation&#xD;
             in the study&#xD;
&#xD;
         11. History of recurring or chronic infections or underlying conditions which may further&#xD;
             predispose patients to serious infection&#xD;
&#xD;
         12. Subjects who are impaired, incapacitated, or incapable of completing study-related&#xD;
             assessments&#xD;
&#xD;
         13. History of allergy to mycophenolate sodium&#xD;
&#xD;
         14. Nausea, vomiting, diarrhea within 1 week before enrollment&#xD;
&#xD;
         15. History of psychosis, seizure, retinopathy&#xD;
&#xD;
         16. Infection 2 weeks before enrollment&#xD;
&#xD;
         17. Heart rate &lt; 60/min at rest&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeng-Hsien Yen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaohsiung Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wen-Chan Tsai</last_name>
    <role>Study Director</role>
    <affiliation>Kaohsiung Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tsan-Teng Ou, MD</last_name>
    <role>Study Director</role>
    <affiliation>Kaohsiung Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cheng-Chin Wu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Kaohsiung Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wan-Yu Sung, MD</last_name>
    <role>Study Director</role>
    <affiliation>Kaohsiung Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chia-Chun Tseng, MD</last_name>
    <role>Study Director</role>
    <affiliation>Kaohsiung Medical University</affiliation>
  </overall_official>
  <results_reference>
    <citation>Willeke P, Schlüter B, Becker H, Schotte H, Domschke W, Gaubitz M. Mycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trial. Arthritis Res Ther. 2007;9(6):R115.</citation>
    <PMID>17986340</PMID>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>February 16, 2016</study_first_submitted>
  <study_first_submitted_qc>February 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2016</study_first_posted>
  <last_update_submitted>September 21, 2016</last_update_submitted>
  <last_update_submitted_qc>September 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaohsiung Medical University</investigator_affiliation>
    <investigator_full_name>Jeng-Hsien Yen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We won't share our data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

